Olema Oncology Advances OP-1250 Into Phase 2 Monotherapy Expansion In Patients With ER+/HER2- Advanced Breast Cancer
SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), today announced the advancement of OP-1250, a complete estrogen receptor